Tuhura Biosciences, Inc. · NASDAQ:HURA
Tuhura Biosciences — Investor Presentation (March 2026)
23 slides from Tuhura Biosciences's investor presentation, March 2026
Slide 1: Overcoming Resistance to Cancer Immunotherapy
Overcoming Resistance to Cancer Immunotherapy March 2026 tuhurabio.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes “forward-looking statements” under the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, and TuHURA’s actual results may differ from its expectations, estimates and projections expressed in its forwa
Slide 3: We are a Phase 3 immuno-oncology company
We are a Phase 3 immuno- oncology company developing three distinct novel technologies and therapeutics to overcome primary and acquired resistance to cancer immunotherapies 3
Slide 4: Investment Highlights
Investment Highlights Overcoming resistance to cancer immunotherapies IFx-2.0 in a Ph3 accelerated approval study in 1st Line Merkel Cell Carcinoma • Top-line data expected 1H 2027 • Confirmatory trial not required • SPA Agreement with the FDA VISTA inhibiting Mab Ph2 study in AML, data expected in
Slide 5: Diversified Immuno-Oncology Pipeline
Diversified Immuno-Oncology Pipeline PROGRAM DRUG CANDIDATE INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Upcoming Milestone 1st Line Merkel Cell Cancer 1H 2027: Phase 3 Keytruda® +/- IFx-2.0 or Topline Results placebo1 IFx-2.0 Innate Immune Tumor-targeted Agonists pDNA Primary Checkpoint Inhibitor
Slide 6: Upcoming Milestones
Upcoming Milestones 2026 2027 1H 2026 2H 2026 1H 2027 Phase 3 enrollment Phase 3 topline results completion IFx-2.0 Tumor-targeted pDNA Phase 2 data at ESMO Phase 2 initiation Phase 2 results TBS-2025 VISTA trial in NPM1 mut VISTA trial in NPM1 mut VISTA Inhibiting mAb r/r AML r/r AML Start IND enab
Slide 7: IFx Technology
IFx Technology Innate Immune Agonists Designed to Overcome Primary Resistance to Checkpoint Inhibitors
Slide 8: IFx-2.0: Mechanism of Action
IFx-2.0: Mechanism of Action Making a Tumor Look Like a Bacterium Initiation of an Innate Immune Response Activation of Tumor Specific T Cells Allows CPI to work where they previously failed 1 Intra-tumoral injection of 3 4 5 pDNA results in expression bacterial protein on surface of tumor – making
Slide 9: Advanced Metastatic Merkel Cell Carcinoma
Advanced Metastatic Merkel Cell Carcinoma 50% of Patients Don’t Respond to 1st Line Keytruda® Keytruda® (pembrolizumab) is the 1st line standard of care for Probability of disease progression at advanced metastatic MCC two years is 26%, 57% and 100% for those with CR, PR and SD, respectively 20% 36%
Slide 10: Phase 1b Study in Advanced Skin Cancer
Phase 1b Study in Advanced Skin Cancer (Merkel Cell and Cutaneous Squamous Cell Carcinoma) Safety evaluable (n=21) TRAEs Dose and Schedule Enrolled n=23 selected: 1-3 lesions, (13 MCC, 10 SCC) Grade 1 35% (8) Weekly x 3 Grade 3 4% (1) Response evaluable Best Overall Median Duration of MCC (n=9) Resp
Slide 11: Single Phase 3 Accelerated Approval Trial
Single Phase 3 Accelerated Approval Trial Designed with OCE1 – Utilized Project Front Runner Initiative 1st line CPI naïve, advanced/metastatic MCC 1:1 Randomization, Placebo, Injection Controlled Trial Primary Endpoint Overall Response Rate (ORR) Key Secondary Endpoint 21of 25 U.S. clinical centers
Slide 12: Phase 2 Trial in MSI-low Deep-Seated Tumors Expands Commercial Opportunity
Phase 2 trial in MSI-low Deep-Seated Tumors Expands Commercial Opportunity Beyond Merkel Cell Carcinoma Image Guidance for Broader Usage Through Interventional Radiology • Biology of 10 resistance is common across tumor types (histology agnostic) • MSI-low and MSS tumors are non-immunogenic • Lack a
Slide 13: TBS-2025 VISTA Inhibiting mAb
TBS-2025 VISTA Inhibiting mAb mutNPM1 Acute Myeloid Leukemia (AML)
Slide 14: Targeting VISTA: a new checkpoint target in AML, MDS
Targeting VISTA: a new Broad Potential in Blood Related Malignancies checkpoint target in AML, MDS VISTA is a novel checkpoint highly expressed on: Strategic Focus and Technology Synergies Leukemic blasts Myeloid Derived Suppressor Cells (MDSCs) Synergy with Delta Quiescent T Cells – VISTA maintains
Slide 15: TBS2025: Scientific Rational for VISTA in AML
TBS2025: Scientific Rational for VISTA in AML Strong Scientific Rational for VISTA in AML • Only checkpoint highly expressed in AML responsible for immune evasion • Presence on leukemic blast correlates with poor survival • Expression driven by most common mutations in AML (DNMT3A, NPM1) • Menin inh
Slide 16: TBS-2025: Inhibiting VISTA in AML to improve Complete Remission
TBS-2025: Inhibiting VISTA in AML to improve Complete Remission Phase 2 Trial Design1 Group 1 Group 2 Menin inhibitor naïve mutNPM1 r/rAML Menin inhibitor exposed mutNPM1 r/rAML • Simon 2 stage design • Exploratory design in menin inhibitor • Stage 1 resistant AML • 14 patients TBS-2025 + menin inhi
Slide 17: Bi-Specific, Bi-Functional Antibody Drug Conjugates ADCs
Bi-Specific, Bi-Functional Antibody Drug Conjugates ADCs First in class immune modulating ADCs *DOR – Delta Opioid Receptor
Slide 18: Reprograming MDSC Immune Suppressing Functions
Reprograming MDSC Immune Suppressing Functions (Novel approach to overcome acquired resistance to cancer immunotherapies) MDSC immunosuppressive activities • MDSC are normally produced during pregnancy; provide immune sanctuary for fetus • Hijacked by tumors, responsible for immunosuppression in the
Slide 19: Delta Opioid Receptor (DOR) – a single target in MDSCs
Delta Opioid Receptor (DOR) – a single target to control expression of multiple immune suppressing genes in MDSCs qPCR assessment of suppressive genes in MDSCs Before and after DOR inhibition ✱✱✱✱ ✱✱ 1.5 1.5 1.5 ✱ 1.5 ✱ Fold change of S100A9 Fold change of NOS2 Fold change of COX2 Fold change of Arg
Slide 20: First in Class Bi-functional, Bi-specific Antibody Drug Conjugates (ADC)
First in Class Bi-functional, Bi-specific Antibody Drug Conjugates(ADC) Differences from Current ADC Approaches Anti-VISTA mAb • Non tumor targeting, internalizing, nor cytotoxic, cell cycle targeting payloads • Bi-specific: • Targets both DOR and VISTA on MDSCs R* Chemica • Bi-functional: l reactiv
Slide 21: Upcoming Milestones
Upcoming Milestones 2026 2027 1H 2026 2H 2026 1H 2027 Phase 3 enrollment Phase 3 topline results completion IFx-2.0 Tumor-targeted pDNA Phase 2 data at ESMO Phase 2 initiation Phase 2 results TBS-2025 VISTA trial in NPM1 mut VISTA trial in NPM1 mut VISTA Inhibiting mAb r/r AML r/r AML Start IND enab
Slide 22: Investment Highlights
Investment Highlights Overcoming resistance to cancer immunotherapies IFx-2.0 in a Ph3 accelerated approval study in 1st Line Merkel Cell Carcinoma • Top-line data expected 1H 2027 • Confirmatory trial not required • SPA Agreement with the FDA VISTA inhibiting Mab Ph2 study in AML, data expected in
Slide 23: Overcoming Resistance to Cancer Immunotherapy
Overcoming Resistance to Cancer Immunotherapy March 2026 tuhurabio.com
TuHURA Biosciences — Investor Presentation (March 2026) on 6ix